Free Trial

PROCEPT BioRobotics (PRCT) Earnings Date, Estimates & Call Transcripts

PROCEPT BioRobotics logo
$81.17 +0.39 (+0.48%)
(As of 12/20/2024 05:40 PM ET)

PROCEPT BioRobotics Latest Earnings Summary

Actual EPS
(Oct. 28)
-$0.40 Beat By $0.09
Consensus EPS
(Oct. 28)
-$0.49

PROCEPT BioRobotics released Q3 2024 earnings on October 28, 2024, reporting an EPS of -$0.40, which beat the consensus estimate of -$0.49 by $0.09. Quarterly revenue rose 66.4% year-over-year to $58.40 million, above analysts' expectations of $53.30 million. With a trailing EPS of -$1.95, PROCEPT BioRobotics' earnings are expected to grow next year, from ($1.75) to ($1.28) per share.

Get PROCEPT BioRobotics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PROCEPT BioRobotics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

PRCT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PRCT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

PROCEPT BioRobotics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242-$0.56-$0.49-$0.53
Q2 20242-$0.55-$0.53-$0.54
Q3 20242-$0.49-$0.48-$0.49
Q4 20242-$0.35-$0.34-$0.35
FY 20248-$1.95-$1.84-$1.90
Q1 20252-$0.38-$0.33-$0.36
Q2 20252-$0.37-$0.30-$0.34
Q3 20252-$0.29-$0.27-$0.28
Q4 20252-$0.19-$0.17-$0.18
FY 20258-$1.23-$1.07-$1.15
Q1 20261-$0.19-$0.19-$0.19
Q2 20261$0.20$0.20$0.20
Q3 20261$0.16$0.16$0.16

PROCEPT BioRobotics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/28/2024Q3 2024-$0.49-$0.40+$0.09-$0.40$53.30M$58.40M
8/1/2024Q2 2024-$0.52-$0.50+$0.02-$0.50$50.10M$53.35M
5/1/2024Q1 2024-$0.55-$0.51+$0.04-$0.51$41.58M$44.50M
2/27/2024Q4 2023-$0.44-$0.54 -$0.10-$0.54$41.79M$43.58M
11/1/2023Q3 2023-$0.53-$0.51+$0.02-$0.51$33.44M$35.10M
7/27/2023Q2 2023-$0.57-$0.56+$0.01-$0.56$30.25M$33.10M
4/27/2023Q1 2023-$0.59-$0.63 -$0.04-$0.63$24.32M$24.40M
2/28/2023Q4 2022-$0.53-$0.56 -$0.03-$0.49$23.70M$23.78M

PROCEPT BioRobotics Earnings - Frequently Asked Questions

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earning data on Monday, October 28, 2024. Learn more on PRCT's earnings history.

PROCEPT BioRobotics issued an update on its FY 2024 earnings guidance on Monday, October, 28th. The company issued revenue guidance of $222.5 million-$223.0 million, compared to the consensus revenue estimate of $217.1 million.

In the previous quarter, PROCEPT BioRobotics (NASDAQ:PRCT) reported ($0.40) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.49) by $0.09. Learn more on analysts' earnings estimate vs. PRCT's actual earnings.

The conference call for PROCEPT BioRobotics's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for PROCEPT BioRobotics's latest earnings report can be read online.
Read Transcript

PROCEPT BioRobotics's earnings report can be found in their filing with the SEC.
View SEC filing

PROCEPT BioRobotics (NASDAQ:PRCT) has a recorded annual revenue of $199.84 million.

PROCEPT BioRobotics (NASDAQ:PRCT) has a recorded net income of -$105.90 million. PRCT has generated -$1.95 earnings per share over the last four quarters.

PROCEPT BioRobotics's earnings are expected to grow from ($1.75) per share to ($1.28) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:PRCT) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners